[HTML][HTML] Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF …
Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK
pathway and cancer progression. Recently, a selective B-RAF inhibitor, vemurafenib
(PLX4032), received clinical approval for treatment of melanoma with B-RAF V600E
mutation. However, patients on vemurafenib eventually develop resistance to the drug and
demonstrate tumor progression within an average of 7 months. Recent reports indicated that
multiple complex and context-dependent mechanisms may confer resistance to B-RAF …
pathway and cancer progression. Recently, a selective B-RAF inhibitor, vemurafenib
(PLX4032), received clinical approval for treatment of melanoma with B-RAF V600E
mutation. However, patients on vemurafenib eventually develop resistance to the drug and
demonstrate tumor progression within an average of 7 months. Recent reports indicated that
multiple complex and context-dependent mechanisms may confer resistance to B-RAF …